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Brain inflammation is a common occurrence following responses to varied insults such
as bacterial infections, stroke, traumatic brain injury and neurodegenerative disorders.
A common mediator for these varied inflammatory responses is prostaglandin E2
(PGE2), produced by the enzymatic activity of cyclooxygenases (COX) 1 and 2. Previous
attempts to reduce neuronal inflammation through COX inhibition, by use of nonsteroidal
anti-inflammatory drugs (NSAIDs), have met with limited success. We are proposing the
two-hit model for neuronal injury—an initial localized inflammation mediated by PGE2
(first hit) and the simultaneous release of adenosine triphosphate (ATP) by injured cells
(second hit), which significantly enhances the inflammatory response through increased
synthesis of PGE2. Several evidences on the role of exogenous ATP in inflammation have
been reported, including contrary instances where extracellular ATP reduces inflammatory
events. In this review, we will examine the current literature on the role of P2 receptors,
to which ATP binds, in modulating inflammatory reactions during neurodegeneration.
Targeting the P2 receptors, therefore, provides a therapeutic alternative to reduce
inflammation in the brain. P2 receptor-based anti-inflammatory drugs (PBAIDs) will retain
the activities of essential COX enzymes, yet will significantly reduce neuroinflammation by
decreasing the enhanced production of PGE2 by extracellular ATP.
Keywords: ATP, microglia, neuroinflammation, NSAIDs, P2 receptors, PBAIDs, prostaglandin E2
INFLAMMATIONWITHIN THE BRAIN
Various environmental factors can lead to inflammation within
the brain. These range from bacterial infections that cause
acute inflammation to neurodegenerative disorders that mediate
chronic inflammation. The inflammation may be restricted to a
local region in focal ischemia or occur in a wider zone during
traumatic brain injury. Inflammation could also result from an
autoimmune response such as multiple sclerosis or in response to
toxins and nerve agents (for general reviews, see Lucas et al., 2006;
Aguzzi et al., 2013). Recent reports implicate inflammation con-
tributing to the pathology of psychiatric disorders such as stress,
depression and schizophrenia (Najjar et al., 2013), in metabolic
syndromes such as obesity and type 2 diabetes (Purkayastha
and Cai, 2013), and even as a response to increased neuronal
activity (Xanthos and Sandkuhler, 2014). Irrespective of the type
of inflammation, the molecular mediators are oftentimes the same
–prostaglandin E2 (PGE2) or cytokines such as interleukin-1β
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis;
ATP, adenosine triphosphate; COX, cyclooxygenase; IL-1β, interleukin-1β;
IRF8, interferon regulatory factor 8; LPS, lipopolysaccharide; MCP1, mono-
cyte chemotactic protein 1; MMP-9, matrix metalloproteinase 9; NSAIDs,
non-steroidal anti-inflammatory drugs; PARP, poly (ADP-ribose) polymerase;
PBAIDs, P2 receptor-based anti-inflammatory drugs; PGE2, prostaglandin
E2; PD, Parkinson’s disease; TNF-α, tumor necrosis factor α; UTP, uridine
triphosphate.
(IL-1β), produced by the activity of resident microglial cells.
Despite brain inflammation playing such a major role in various
CNS disorders, successful therapeutic strategies to overcome it are
still lacking.
PGE2 is produced by the action of cyclooxygenases (COX)
which mediate the first committing step in its synthesis from
arachidonic acid (Akundi et al., 2005). The constitutively active
COX-1 isoform is believed to be responsible for the major-
ity of PGE2 formed in the body. However, it is the growth
factor-, cytokine- or mitogen-inducible COX-2 that emerged
as the isoform responsible for the massive release of PGE2
during inflammation of all types—systemic, central, acute or
chronic. The COX enzymes have been a therapeutic target
in a multitude of disorders, ranging from fever and pain
to cancer, rheumatoid arthritis, and Alzheimer’s disease (AD;
Yedgar et al., 2007). Their importance can be judged from the
widespread use of aspirin as an analgesic and antipyretic; and
the promise of nonsteroidal anti-inflammatory drugs (NSAIDs)
against spreading neurodegeneration in AD (Szekely and Zandi,
2010). However clinical trials failed to not only halt the pro-
gression of dementia in AD patients but also showed increased
risks of myocardial infarction and stroke (Jüni et al., 2004).
An essential lesson learnt from the debacle of NSAIDs was
that the two isoforms of COX do not functionally substi-
tute one another but each remains indispensable in certain
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functions. COX-2 stands on a delicate balance—the neuronal
isoform plays an important role in synaptic plasticity, mem-
ory consolidation and cortical development while the microglial
isoform mediates neuroinflammation. Targeting COX enzymes,
therefore, requires a careful consideration of the benefit-to-risk
ratio.
NEUROINFLAMMATION: A TWO-HIT MODEL
An interesting observation in the past decade and half showed
that the inflammatory response of microglia—the release of
mature IL-1β from lipopolysaccharide (LPS)-primed cells—could
be significantly modulated with the addition of exogenous adeno-
sine triphosphate (ATP; Ferrari et al., 1997). More diversi-
fied studies showed that ATP is able to mediate the release
of PGE2 in IL-1β-treated astrocytes (Xu et al., 2003) or in
LPS-activated macrophages (Barberà-Cremades et al., 2012). We
found a similar synergistic effect of ATP on LPS-mediated PGE2
release in primary rat microglial cells (unpublished observa-
tion). These studies conclusively showed that exogenous ATP
significantly modulates inflammation. In this review, we are
proposing the two-hit model for neuroinflammation. The first hit
is the injury itself—nerve injury, bacterial infections, hypoxia-
ischemia, autoimmune reactions or proteopathies associated
with neurodegeneration—leading to the activation of glial cells
(Figure 1). The second hit is the release of large pools of cytosolic
ATP from damaged neurons into the extracellular milieu, in
response to direct injury or following glial cell activation. This
excess ATP, despite mechanisms regulating their concentration
outside the cell, activates a wide variety of purinergic receptors
present on cells in the vicinity, thus modulating glial activity and
neuronal response to inflammation. Such a model was earlier
proposed for the release of mature IL-1β following bacterial
infections (Ferrari et al., 2006). Identifying the pro-inflammatory
receptors of ATP, and targeting them pharmacologically, will
significantly diminish the dramatic release of prostanoids and
cytokines to clinically manageable levels; thus, balancing their
functional roles in active defence and tissue repair.
ATP: THE COMMON DENOMINATOR FOR VARIED
INFLAMMATORY INSULTS
Both healthy neurons and glial cells carry ATP, in millimolar
concentrations, within presynaptic vesicles and granules, respec-
tively (Abbracchio et al., 2009). Neuronal ATP serves as a neu-
rotransmitter while astrocytic ATP allows distant astrocytes to
communicate with each other and modulate neuronal response.
However, the release of ATP by neurons or astrocytes is usually
very low, in the nanomolar range. Furthermore, the extracellular
concentration of ATP is dependent on the regional distribu-
tion and local activity of synaptic ectonucleotidases CD28/CD39
which convert ATP to ADP and AMP, CD73 which converts
AMP to adenosine, and nucleoside diphosphate kinase whose
transphosphorylating activity maintains the exogenous levels of
various nucleotides in steady state (Lazarowski et al., 2003). This
steady state balance is, however, disrupted during pathological
conditions when damaged neurons and chronically activated glial
cells release dramatic levels of ATP, uridine triphosphate (UTP)
and other intracellular nucleotides.
Not only neuropathological conditions even systemic inflam-
mation leads to an increase in exogenous ATP within the CNS
(Gourine et al., 2007). In fact the release of ATP in response
to tissue injury is a universal phenomenon also seen in plants
at sites of physical wounding (Choi et al., 2014). Efflux of
ATP into the extracellular space is a common universal “stress
signal”, leading to the evolution of receptors for ATP to rec-
ognize this “danger” and initiate a stress response. Mammals
evolved purinergic receptors with varying specificities for ligands
such as ATP, ADP, UTP, UDP, UDP-sugars or adenosine, and
diverse range of intracellular signaling mechanisms downstream
to receptor activation. Nucleotides act on P2 receptors, with seven
ionotropic P2X receptors gating Na+, K+, and especially Ca2+
FIGURE 1 | The two-hit model of neuroinflammation. The ATP-mediated
enhancement of neuroinflammation can be explained through the two-hit
model. A variety of insults, such as bacterial LPS, various cytokines, or
amyloid peptides, can act as the first hit, resulting in microglial activation,
COX-2 induction and PGE2 release. The second hit, following neuronal injury,
death or persistent glial cell activation, results in the release of ATP, which
acts on both neuronal and glial P2 receptors, leading to enhanced microglial
PGE2 release. NSAIDs target COX enzymes affecting the housekeeping roles
of PGE2. ATP potentiates the effects of first hit multi-fold, and thus, would be
the most relevant target for therapeutic intervention. By acting on P2
receptors, PBAIDs are believed to reduce PGE2 to pre-inflammatory levels
without affecting the activity of COX enzymes.
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ions, and eight G protein-coupled metabotropic P2Y receptors
(Abbracchio et al., 2009). Adenosine, on the other hand, acts
on adenosine receptors, of which A1 and A3 adenosine recep-
tors inhibit, while A2A and A2B adenosine receptors stimulate
adenylyl cyclase (Fredholm, 2010). Recently ATP receptors have
also been identified in plants which are activated in response
to tissue wound (Choi et al., 2014). Called DORN1 (Does not
Respond to Nucleotides 1), these receptors, much like their mam-
malian counterparts, show high affinity to ATP and alter Ca2+
flow.
EXOGENOUS ATP HAS BOTH POSITIVE AND NEGATIVE
ROLES IN INFLAMMATION
The presence of functionally active purinergic receptors on
microglia indicates the likelihood of astrocyte-microglia crosstalk
(Verderio and Matteoli, 2001). Such a communication enhances
microglial surveillance system and their response to inflamma-
tion within the CNS. Indeed, neuronal and astrocytic release
of ATP during traumatic brain injury causes rapid microglial
chemotactic response (Davalos et al., 2005). At the site of
injury, exogenous ATP mediates the release of pro-inflammatory
cytokines and PGE2 (Xu et al., 2003; Ferrari et al., 2006; Xia
and Zhu, 2011). The end effect of this synergism is the pro-
duction of pathological levels of inflammatory cytokines and
prostanoids.
While the above reports suggest extracellular ATP as proin-
flammatory, others have reported to the contrary. In LPS-primed
cells, ATP inhibited the release of cytokines from spinal cord
microglia (Ogata et al., 2003), nitric oxide (NO) release in BV-2
microglia (Brautigam et al., 2005), and pro-inflammatory mark-
ers such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-
6) and NO in primary microglia (Boucsein et al., 2003). Since
TNF-α and IL-6 also have neuroprotective roles (Suzuki et al.,
2004; Noguchi et al., 2013), the above inhibitory action of ATP
may actually be detrimental to the organism. Increases in exoge-
nous ATP need not always be hazardous—extracellular levels
of adenosine increases 6- to 31-fold within the hippocampus
of patients with epilepsy, but acts as a natural anticonvulsant
terminating seizure (During and Spencer, 1992). Interestingly,
cancer cells evade surveillance by up-regulating a subpopulation
of regulatory T cells expressing ectonucleotidases CD39 and CD73
to exploit the immunosuppressive nature of adenosine (Whiteside
and Jackson, 2013). Early development of nervous system is
dependent on purinergic signals, which in concert with growth
factors, regulate the number of proliferating and differentiating
neural stem cells (Ulrich et al., 2012).
P2 RECEPTORS DETERMINE THE EVENTUAL EFFECT OF
EXTRACELLULAR ATP
P2X7 RECEPTORS
The specific roles of P2 receptors in neuroinflammation are
still being uncovered. The subject is still in its teens, starting
with the discovery of ATP enhancing IL-1β release in activated
immune cells (Ferrari et al., 1997). LPS-mediated activation
of toll-like receptor 4 leads to the formation of the inflam-
masome complex wherein IL-1β processing occurs (Martinon
et al., 2002). However, release of IL-1β requires loading of the
inflammasome complex into the secretory lysosome, or the for-
mation of membrane blebs—either mechanism triggered through
P2X7 receptor-mediated K+ efflux (Ferrari et al., 2006; di Virgilio,
2007). As a result, the effect of ATP is dependent on cells primed
with LPS, and conversely, LPS does not release IL-1β in the
absence of P2X7 receptors (Solle et al., 2001). Pannexin 1, a gap
junction-related protein, has been shown to be responsible for
the release of ATP from dying cells, leading to the activation
of the inflammasome and recruitment of phagocytes (Dahl and
Keane, 2012). Intraperitoneal injection of LPS results in two-four-
fold higher detection of ATP in the mouse peritoneum (Barberà-
Cremades et al., 2012). Systemic administration of LPS markedly
increases the expression of P2X7 receptors in the brain (Choi et al.,
2007). LPS- or IL-1β-mediated febrile response is greatly reduced
in mice with genetic or pharmacological loss of P2X7 receptors
(Barberà-Cremades et al., 2012). ATP and the preferential P2X7
agonist, 2′(3′)-O-(4-benzoylbenzoyl) ATP (BzATP) induce the
secretion of cytokines IL-6 and TNF-α in wildtype microglia but
not in cells derived from P2X7−/− mice (Shieh et al., 2014). These
reports underline the importance of P2X7 receptors in mediating
inflammation, especially in the release of IL-1β (Ferrari et al.,
2006). The low affinity of P2X7 receptors for extracellular ATP
ensures their activation occurs only under pathological conditions
where excess ATP is found, further supporting the notion of
exogenous ATP as an “alarm” signal.
Immunohistochemical analysis of AD brains reveal significant
levels of P2X7 receptors colocalized with activated microglia, an
observation that was also found in the hippocampus of rats
injected with Aβ1-42 (McLarnon et al., 2006). Aβ triggers ATP
release, membrane permeabilization and IL-1β secretion in wild-
type but not in P2X7−/− mouse (Sanz et al., 2009). In fact,
overexpression of P2X7 receptor itself, in the absence of any pro-
inflammatory stimuli, can drive the activation and proliferation
of microglial cells (Monif et al., 2009). Similarly, exposure to high
levels of extracellular ATP can also tilt the signaling mechanism
from a P2X7-phosphatidylinositol 3-kinase/Akt-mediated growth
pathway to a novel P2X7-AMPK-mammalian target of rapamycin
(mTOR)-mediated autophagic pathway, as observed in tumor
cells (Bian et al., 2013). Rapamycin reduces neuroinflammation
and brain lesions in a mouse model of Leigh syndrome (Johnson
et al., 2013). In astrocytes, inhibition of mTOR significantly
reduces the stability of inducible nitric oxide synthase (iNOS)
mRNA (Lisi et al., 2011). However, in microglia, blocking of
mTOR pathway in activated cells leads to enhanced PGE2 syn-
thesis (de Oliveira et al., 2012). Activated microglia downregulate
microRNA, miRNA-200b, which leads to increased c-Jun N-
terminal kinase (JNK) activity leading to increased iNOS expres-
sion (Jadhav et al., 2014). These observations suggest that the role
of mTOR in neuroinflammation is cell-type specific and depends
on both epigenetic factors and the presence of inflammatory
stimuli.
Gene expression studies in Aβ-treated microglia derived from
human post-mortem brains, in fact, suggest that the expression
of pro-inflammatory genes are largely up-regulated at the expense
of genes involved in Aβ phagocytosis and removal (Walker et al.,
2006). Activated P2X7 receptors impair lysosomal function and
instead stimulate the release of autolysosomal contents into the
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extracellular space, possibly leading to the increased secretion
of IL-1β or amyloidogenic proteins (Takenouchi et al., 2009).
In corollary, silencing of P2X7 receptors in Aβ-stimulated cells
leads to a decreased release of pro-inflammatory cytokines and
a marked increase in the phagocytosis of Aβ1–42 peptide (Ni
et al., 2013). P2X7 receptors, therefore, turn phagocytic (neu-
roprotective) microglia into inflammatory (neurodegenerative)
phenotype.
Expression of P2X7 receptors is also up-regulated in Hunt-
ington’s disease and amyotrophic lateral sclerosis (ALS; Díaz-
Hernández et al., 2009). In microglia isolated from superoxide
dismutase SOD1-G93A mutant mouse model of ALS, activation
of P2X7 receptors enhances oxidative stress (Apolloni et al.,
2013). Oxidative stress drives the nitration of 90 kDa heat-
shock protein (Hsp90), which mediates cell death through P2X7
receptors (Franco et al., 2013). Nitrated Hsp90 is found in the
motor neurons of patients with ALS; and as expected, deletion
of P2X7 receptors prevents the neurotoxic effects of nitrated
Hsp90.
Imbalances in energy homeostasis are associated with neu-
rodegenerative disorders (Akundi et al., 2013). Over-activation
of poly (ADP-ribose) polymerase 1 (PARP1) contribute towards
dopaminergic degeneration in Parkinson’s disease (PD), which
is completely absent in PARP1−/− mice (Kim et al., 2013).
PARP1 activation leads to depletion of cytosolic NAD+. Replen-
ishment of NAD+ prevents PARP1-mediated neuronal death
(Alano et al., 2010). Exogenous NAD+, surprisingly, enters neu-
rons through the dilated P2X7 receptor-gated channels, marking
a neuroprotective role for the otherwise proinflammatory P2X7
receptors.
Among other neuroprotective roles, various in vitro models
show that activation of P2X7 receptors stimulates α-secretase
activity leading to the shedding of non-amyloidogenic soluble
amyloid precursor protein (APP; Darmellah et al., 2012). On
the contrary, inhibition of P2X7 receptors in a transgenic mouse
for mutant human APP show a significant decrease in the num-
ber of amyloid plaques through increased activity of α-secretase
(Diaz-Hernandez et al., 2012). Such opposing roles could be best
explained with the discovery of a shorter, natural, splice variant
of P2X7 receptor that exhibits neurotrophic properties (Adinolfi
et al., 2010). Though it remains to be investigated, it is probable
that the truncated P2X7 receptors induce α-secretase activity
while the longer isoforms are inhibitory. The factors that mediate
the retention or deletion of the C-terminal part of P2X7 receptors
are not yet known. Such contrasting roles of P2X7 receptors have
also been identified in other cellular systems such as cancer (Feng
et al., 2006). The distribution of short and long isoforms of P2X7
within the receptor heterotrimer most likely determines its overall
trophic or toxic nature.
P2X4 RECEPTORS
An interesting use of neuronal P2 receptors as “flags” for
microglial recognition has been reported. In the mutant super-
oxide dismutase SOD1 mouse model of ALS, degenerating motor
neurons typically express P2X4 receptors for the recruitment and
eventual engulfment by activated microglia (Casanovas et al.,
2008). Unlike a typical cell undergoing apoptosis, P2X4-positive
neurons neither show chromatin condensation nor caspase 3
activity; rather exhibit loss of neuronal NeuN marker and
recruitment of microglial cells. It is not just restricted to motor
neurons but to other degenerating neurons affected with ALS—
serotonergic neurons of raphe nucleus, noradrenergic neurons of
locus coeruleus, and Purkinje cells in the cerebellum. In Aβ1-42-
treated neurons that do undergo caspase 3-mediated apoptosis,
increased surface expression of P2X4 receptors occurs due to the
unique presence of a putative caspase 3 cleavage site within the
C terminus region (Varma et al., 2009). Hence, overexpression
of P2X4 receptors enhances Aβ-induced neuronal death, while
receptor inhibition subdues cell death. These reports form the
basis for our hypothesis that surface expression of P2X4 recep-
tors may serve as markers for degenerating neurons, attracting
microglial cells for eventual engulfment.
On the other hand microglial P2X4 receptor expression is
associated with increased neurophagic activity (Cavaliere et al.,
2003). Knocking out P2X4 receptors results in poorer microglial
activation and loss of PGE2-mediated inflammatory pathway
(Ulmann et al., 2010). P2X4 receptor forms a large conductance
pore on the cell surface affecting ionic balance, thus mediat-
ing the release of proinflammatory substances. Constitutively,
P2X4 receptors are trafficked into late endosomes and remain
resistant to lysosomal degradation (Robinson and Murrell-
Lagnado, 2013). Such a mechanism prevents the “flagging” of
healthy neurons or the “activation” of microglia under normal
physiology.
OTHER P2X RECEPTORS
Slow neurodegeneration, following axotomy, shows an upregula-
tion of P2X1 and P2X2 receptors, synchronous with upregulation
of neuronal nitric oxide synthase (nNOS; Viscomi et al., 2004).
P2X receptors further mediate translocation of nNOS to the
plasma membrane (Ohnishi et al., 2009). In an animal model
of PD, dopamine denervation upregulates P2X1, P2X3, P2X4 and
P2X6 receptors on nigral GABAergic neurons to compensate the
loss of dopamine (Amadio et al., 2007). Coincidentally, within the
substantia nigra, two out of five groups of GABAergic neurons,
but none of the five groups of dopaminergic neurons, express
nNOS (González-Hernández and Rodríguez, 2000). Whether P2X
and nNOS are upregulated within the same cell during neu-
rodegeneration is not known; however, coordinated activation of
purinergic and nitrergic mediators seems a likely event during
neuroinflammation.
P2Y RECEPTORS
The metabotropic P2Y receptors play a major role in neuron-
glia communication. Neuronal injuries activate astrocytic P2Y1
receptors leading to the release of PGE2, causing reactive gliosis
(Xia and Zhu, 2011), or glutamate, mediating synaptic modula-
tion (Domercq et al., 2006). Blocking of P2Y1 receptors there-
fore reduces glial activity (Davalos et al., 2005) and improves
cognitive outcome following traumatic brain injury (Choo et al.,
2013). In the AD brain, P2Y1 receptors are localized in the
neurofibrillary tangles and neuritic plaques (Moore et al., 2000).
In contrast, there is a selective loss of P2Y2 receptors correlat-
ing with worsening neuropathological scores (Lai et al., 2008).
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This is not surprising since P2Y2 receptors stimulate α-secretase
activity (Camden et al., 2005). In addition, P2Y2 receptors medi-
ate microglial phagocytosis of fibrillar forms of Aβ in a mouse
model of AD (Ajit et al., 2014). The soluble Aβ peptides are
instead cleared through ATP-dependent P2Y4 receptor-mediated
pinocytosis (Li et al., 2013). In fact soluble Aβ1-42 itself induces
ATP release, auto-stimulating P2Y4 receptors in microglia, thus
mediating its own clearance. Degradation of extracellular amy-
loid peptides is also performed by metallopeptidases such as
matrix metalloproteinase 9 (MMP-9), whose secretion is upregu-
lated following inhibition of the tonically active P2Y14 receptors
(Kinoshita et al., 2013). These reports suggest that the loss of
P2Y2 and P2Y4 receptors or an overactivation of P2Y1 and P2Y14
receptors alter the steady state levels of amyloid peptides leading
to AD.
Both P2Y2 and P2Y4 receptors are preferentially expressed
in perivascular astrocytes, and in response to exogenous ATP,
mediate increased levels of cytosolic calcium within their end-
feet processes (da Silva et al., 2009). As a result, P2Y receptors
influence the permeability of blood-brain barrier through induc-
tion of endothelial nitric oxide synthase (eNOS). Activated glial
cells also induce the expression of chemokines such as monocyte
chemotactic protein 1 (MCP1) leading to the CNS recruitment
of monocytes (Kim et al., 2011). Interestingly, MCP1 deficiency
decreases microglial phagocytosis of Aβ oligomers, thus con-
tributing to progressive amyloidosis (Kiyota et al., 2013).
UDP is the ligand of choice for P2Y6 receptors. Activated
P2Y6 receptors trigger a change in microglial phenotype—
from active motile/surveillance cells to active neuron devour-
ing/phagocytic cells (Koizumi et al., 2007). The neurophagic
activity of microglial cells is potentiated by TNF-α, LPS or Aβ
peptides, and delayed through P2Y6 receptor antagonists (Neher
et al., 2014). Furthermore, activated P2Y6 receptors block dilation
of P2X4 receptor-mediated channels, shifting microglial pheno-
type from inflammatory to phagocytic cells (Bernier et al., 2013).
Blocking of P2Y6 receptors increases neuronal survival suggesting
that phagocytosis is not limited to degenerating neurons alone but
non-specifically targets “stressed-but-otherwise-viable” neurons
as well (Emmrich et al., 2013). Irrespective of the type of insult,
the release of UDP signals microglia to initiate indiscriminate
phagocytosis found in neurodegenerative disorders.
The migration of microglial cells to the site of injury is medi-
ated by P2Y12 receptors (Haynes et al., 2006). In mice lacking
P2Y12 receptors, microglia fail to polarize and migrate towards
the lesion site while overactivation of P2Y12 receptors enhances
neuroinflammation. As a result P2Y12+/− mice show lesser sever-
ity of neuronal injury following cerebral ischemia compared to
P2Y12+/+ littermates (Webster et al., 2013). Interestingly, loss of
the transcriptional factor interferon regulatory factor 8 (IRF8)
suppresses microglial chemotaxis (Masuda et al., 2014). Irf8−/−
microglia show reduced expression of P2Y12, P2X4 and adenosine
A3 receptors—all involved in microglial activation and migration
to the site of injury. As a result, Irf8−/− mice are resistant to
experimental autoimmune encephalitis (EAE)—a mouse model
of multiple sclerosis (Yoshida et al., 2014).
ADP, formed by the activity of ectonucleotidases on extracellu-
lar ATP, is the preferred ligand for P2Y13 receptors. Ubiquitination
at its C-terminal end leads to proteasomal degradation and
poor surface expression (Pons et al., 2014). However its surface
expression increases in response to oxidative stress and genotoxins
such as cisplatin or UV irradiation (Morente et al., 2014). In the
red blood cells, ADP-activated P2Y13 receptors show a negative
feedback loop by inhibiting ATP release (Wang et al., 2005). Such
a mechanism ensures additional regulation of extracellular ATP
during neuronal injuries by restricting the lesion area such that
undamaged and far away neurons which are exposed to ADP are
not activated.
ADENOSINE RECEPTORS
Enhanced neuroinflammation and microglial activity is a feature
of A1 adenosine receptor knockout mice (A1AR−/−), suggesting
that activation of A1ARs is neuroprotective under pathologi-
cal conditions (Luongo et al., 2014). On the other hand, A2A
receptors facilitate glutamate release, and their association with
ectonucleotidase, CD73, implies A2A receptors are activated under
pathological conditions when excess extracellular ATP is found
(Augusto et al., 2013). Hence A2A receptor antagonists such as
caffeine limit the pathology of neurodegenerative disorders such
as AD and PD. Interestingly, in mouse models of senescence,
A1ARs significantly decrease with age while A2A receptors increase
with age (Castillo et al., 2009). A higher density of A2A receptors
in the putamen of PD patients also correlates with increasing
motor symptoms (Varani et al., 2010). A2A receptors induce
microglial COX-2 expression (Fiebich et al., 1996) and inhibit
astrocyte glutamate uptake by interacting with the α2 subunits
of Na+/K+-ATPase (Matos et al., 2013). Though activation of
A1ARs and inhibition of A2A receptors provide neuroprotec-
tion in the adult brain, the opposite is true for the embry-
onic brain. Chronic hypoxia mediates accelerated maturation of
oligodendrocyte progenitor cells leading to hypomyelination and
ventriculomegaly in mice (Akundi and Rivkees, 2009). Deletion
of A1ARs or early intervention with caffeine rescues embryos
against hypoxia-mediated white matter injury (Back et al., 2006).
Similarly, hypoxic ischemia-mediated brain damage was more
profound in newborn A2A−/− mice compared with their wildtype
littermates (Adén et al., 2003). Similarly, it has been observed
that A2A receptor agonists show synergy with agonists of cer-
tain toll-like receptors, such as TLR2, 4, 7 and 9, in selectively
upregulating the expression of vascular endothelial growth factor
and downregulating the release of TNF-α (Pinhal-Enfield et al.,
2003). Such a synergistic mechanism provides an angiogenic role
for macrophages making it relevant in the aftermath of cerebral
ischemia.
Adenosine A3 receptors mediate microglial process extension
(Ohsawa et al., 2012). Agonists of A3 receptors thereby provide
neuroprotection against ischemia (Choi et al., 2011). However,
during chronic neuroinflammation microglia undergo process
retraction through upregulation of adenosine A2A receptors (Orr
et al., 2009). A2A receptor-dependent process retraction is also
seen in the substantia nigra of mice treated with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 5 days (Gyoneva
et al., 2014). A2A receptor-mediated loss of process extension
(due to A3 receptors) and chemotaxis (due to P2Y12 receptors)
thereby dampens microglial response to injury. Microglial cells
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also express α7 nicotinic acetylcholine receptor. Activation of
these receptors attenuates neuroinflammation in a mouse model
of MPTP (Liu et al., 2012). Coincidentally, nicotinic acetylcholine
receptor stimulation mediates dopamine release in the rat stria-
tum which is negatively regulated by agonists of adenosine A2A
receptors (Garção et al., 2013). These observations suggest that
adenosine A2A receptors regulate various neurotransmitter sys-
tems, and use of specific antagonists of A2A receptors, therefore,
show potential as therapeutic alternatives for PD (Threlfell et al.,
2012).
TARGETING P2 RECEPTORS MAY BE AN ATTRACTIVE
THERAPEUTIC APPROACH OVER COX2 INHIBITION
Neuroinflammation in AD was promisingly approached through
the use of NSAIDs (Szekely and Zandi, 2010). Following fail-
ures in clinical trials, the AD Anti-inflammatory Prevention
Trial (ADAPT) group found that neither celecoxib nor naproxen
prevented AD in adults with a family history of dementia
(Breitner et al., 2013). The drawback of using COX inhibitors
lies in the ubiquitous presence and role of its product, PGE2.
PGE2 plays an important role in gastro-intestinal (GI secretion,
bowel motility), cardiovascular (regulates blood pressure), renal
(hemodynamics in the glomeruli), and reproductive (embryo
implantation, uterine contraction) systems; and within the CNS,
regulates body temperature, sleep-wake cycle, memory consoli-
dation and synaptic plasticity. The relative contribution of either
COX isoforms in mediating the above functions is unclear. Selec-
tive COX-2 antagonists were designed to target the excess PGE2
formed during neuroinflammatory episodes with the consider-
ation that the more ubiquitous COX-1 would suffice for the
production of physiological levels of PGE2. However, despite
better gastrointestinal safety ratio, selective COX-2 inhibitors
showed increased risks of myocardial infarction, stroke, sys-
temic and pulmonary hypertension, and sudden cardiac death
(Jüni et al., 2004). The multiple deaths led to the eventual
withdrawal of COX-2 inhibitors such as rofecoxib leading to
sweeping lawsuits and wider criticism of the drug licensing
procedures.
In this scenario targeting P2 receptors, which modulate PGE2
synthesis, comes as a promising therapeutic possibility (Figure 1).
The rat COX-2 promoter carries consensus sequences for tran-
scription factors such as nuclear factor κB (NF-κB), NF-IL6,
AP-1 and cAMP-responsive element (Tanabe and Tohnai, 2002).
In addition, COX-2 can also be epigenetically regulated with
hypermethylation responsible for its silencing in various types
of cancer (Lodygin et al., 2005; Castells et al., 2006). Epige-
netic contribution in the development of multiple sclerosis and
neurodegenerative disorders is slowly being recognized, although
evidences for such changes on P2 receptor genes is not yet
known (Noh et al., 2012; Koch et al., 2013; Qureshi and Mehler,
2013). Furthermore, COX-2 is posttranscriptionally regulated as
well. The human COX-2 mRNA contains at least 23 AU-rich
elements (AREs) in the 3′-untranslated region (UTR) conferring
to its instability (Shaw and Kamen, 1986). The interactions of
ARE-binding protein with the 5′-methylguanosine cap-binding
protein and polyadenosine tail-binding protein can either further
stabilize the mRNA or lead to its degradation through recruitment
of deadenylases (Dean et al., 2004). The p38 mitogen-activated
protein kinase plays a critical role in the post-transcriptional
regulation of several proinflammatory genes through controlling
the phosphorylation status of these binding proteins (Clark et al.,
2003). Other proteins that bind to COX-2 ARE and lead to its
mRNA stabilization include the heat shock protein hsp70 (Kishor
et al., 2013), and the RNA-binding protein HuR which inhibits
the destabilization of COX-2 mRNA mediated by microRNA
miR-16 (Young et al., 2012). Another regulator is the hetero-
geneous nuclear riboprotein A1 (hnRNP-A1) whose declining
levels have been correlated with the severity of symptoms in
various neurodegenerative diseases including AD (Bekenstein and
Soreq, 2013). It was recently reported to regulate IL-6 transcrip-
tion, with overexpression of hnRNP-A1 increasing IL-6 expres-
sion and knockdown leading to reduced IL-6 synthesis (Zheng
et al., 2013). Post-transcriptional and post-translation regulation
of various P2 receptors is not yet known, although the vari-
ous alternate splicing mechanisms as shown in P2X7 (Adinolfi
et al., 2010) and adenosine A1 receptor (Ren and Stiles, 1994)
suggest their involvement. Transcription factors downstream of
P2 receptor activation bind to most of the COX-2 promoter
consensus sequences (Brautigam et al., 2005; Ferrari et al., 2006;
Lenertz et al., 2011). P2X7 receptor antagonists present them-
selves as appropriate therapeutic alternatives to specific COX-2
inhibitors based on several evidences implicating them in neu-
roinflammation. Currently a few P2 receptor antagonists have
advanced to clinical trials (Arulkumaran et al., 2011; North
and Jarvis, 2013). It sets the stage for the potential role of P2
receptor-based anti-inflammatory drugs (PBAIDs) in targeting
neuroinflammation.
A considerable roadblock in the design of PBAIDs is inherent
in the diversity of P2 receptors. The conflicting reports on the
neuroprotective and pro-inflammatory roles of various P2 recep-
tors stems from the limited understanding of the actual types of
receptors expressed, which may differ between cell types, species,
age, and physiological status (Crain et al., 2009; Serrano et al.,
2012). Nerve injury indiscriminately releases nucleotides of all
kinds, including functionally opposing ones. The predominant
ligand concentration depends on the distribution and activity
of ectonucleotidases. Most studies utilize pharmacological agents
which exhibit receptor promiscuity and have been characterized
on purified homomers. However, not only surface P2 receptor
density changes under pathological conditions, there is also the
possibility of formation of heteromultimers (such as P2X2/6,
or P2X4/6, and even P2X2/4/6) with altered ligand affinity and
functions (Robinson and Murrell-Lagnado, 2013). The long and
short splice variants of P2X7 receptor have opposing roles on cell
growth and death (Adinolfi et al., 2010). Finally, an ideal PBAID
has to overcome potential possibilities of receptor compensation.
This was particularly evident in the failure of neuroprotection in
P2X7−/− mice where higher numbers of functionally compen-
sating P2X4 receptors were found instead (Hracskó et al., 2011).
In another example, P2Y12−/− mice show delayed microglial
response to injury; however, other signaling mechanisms did
ensure that microglia reached the site of injury despite the delay
(Haynes et al., 2006). The P2X2-P2X5 heterotrimer is functionally
analogous to P2X7 receptors, including pore dilation, membrane
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blebbing and phosphatidylserine exposure (Compan et al., 2012).
Such rich receptor diversity allows P2X receptors to functionally
compensate the loss of other family members. Therefore, more
studies are required to correctly identify the aggravating P2 recep-
tor contributing to neuroinflammation. Because of the functional
diversity of P2 receptors, PBAIDs should be carefully chosen to
target the disease at the appropriate stage where benefit outweighs
risk.
SUMMARY
Conventionally COX-2 has been a target in various inflamma-
tory disorders. However, the failure of NSAIDs and selective
enzyme inhibitors reveal the importance of COX-2 not only in
various physiological activities but also in tissue repair following
neuronal injury. The COX enzymes maintain a delicate balance
of tissue scavenging and tissue repair during neuroinflamma-
tion. An imbalance could lead to excessive PGE2 activity leading
to increased tissue damage or chronic inflammation. All cells
within the vertebrate system upon damage (hit one) release large
amounts of ATP (hit two) into the extracellular space. The effect
of released ATP depends on the nature of two downstream
factors—(1) the type of receptors present on cells within the
vicinity of the injury; and (2) the distribution and activity of
hydrolyzing ectonucleotidases. In large quantities, ATP poten-
tiates the inflammatory reaction while other nucleotides have
various modulatory roles in shaping the outcome of inflam-
mation (summarized in Figure 2). PBAIDs aim to reduce the
effect of second hit by targeting P2 receptors responsible for
FIGURE 2 | P2 receptors modulate neuroinflammation. A simplified model
based on the literature mentioned in this review summarizes the interactions
between neurons and glial cells. Pro-inflammatory signals modulate
P2X7-mediated release of IL-1β and surface expression of P2X4 receptors in
the presence of ATP released by degenerating neurons and reactive
astrocytes. On the surface of neurons, P2X7 receptors mediate apoptosis
with caspase 3-dependent expression of P2X4 receptors as “flags” for
microglial engulfment. Microglial migration to sites of insult is mediated by
P2Y12 and adenosine A3 receptors and its neurophagic activity through P2Y6
receptors. While A1 adenosine receptors inhibit general inflammatory
pathways, A2a receptors activate COX-2 as well as retract microglial
processes. In healthy neurons, truncated P2X7 and P2Y2 receptors enhance
α-secretase activity, preventing the formation of amyloid deposits. Amyloid
formation is also immediately cleared through microglial phagocytosis,
mediated by P2Y2 receptors; pinocytosis, through P2Y4 receptors; and
activity of MMP-9, inhibited by the tonic activity of P2Y14 receptors.
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inflammation-enhancement rather than the COX enzymes medi-
ating PGE2 synthesis. By not interfering with the COX system
PBAIDs, unlike NSAIDs, retain the housekeeping functions of
PGE2, but vastly reduce the pathology through P2 receptor
inhibition. Identifying the target P2 receptor, and designing a
selective PBAID, remains a challenge for future therapeutic suc-
cesses in neuroinflammation. Surface expression of P2 receptors
under certain pathological conditions may depend on epigenetic
stimuli. Silenced P2 receptors which were once active during
neural development could be reprogrammed in the event of tissue
injury. A global study of P2 receptor density and mutations that
affect their binding to specific nucleotides, may identify newer
insights into the susceptibility of neurodegenerative disorders to
specific populations. Furthermore, it is essential to understand
the activity of various ectonucleotidases since the steady-state
levels of various nucleotides have contrasting outcome in neu-
roinflammation. Therapeutically increasing the activity of spe-
cific ectonucleotidases following excessive ATP release is another
approach to counter neuroinflammation. Finally, the two-hit
hypothesis can also be extended to various other inflammatory
disorders such as arthritis, toxin exposures including nerve gas
poisoning, in the inflammatory model of cancer, and in psy-
chological stress and depression. More studies in these areas
will provide new roles for PBAIDs as effective anti-inflammatory
drugs.
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